Clinical implications of chromatin accessibility in human cancers

May 05, 2020

Volume 11, Issue 18 of @Oncotarget Clinical implications of chromatin accessibility assessed by ATAC-seq profiling in human cancers especially in a large patient cohort is largely unknown.

In this study, the authors analyzed ATAC-seq data in 404 cancer patients from the Cancer Genome Atlas, representing the largest cancer patient cohort with ATAC-seq data, and correlated chromatin accessibility with patient demographics, tumor histology, molecular subtypes, and survival.

Chromatin accessibility, especially on the X chromosome, is strongly dependent on patient sex, but not much on patient age or tumor stage.

Dr. Yuexin Liu from The Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA said, "Cancer is a heterogeneous disease with a diversity of cell types which thus play a deterministic role on patient outcome or therapeutic responses."

"Cancer is a heterogeneous disease with a diversity of cell types which thus play a deterministic role on patient outcome or therapeutic responses."

- Dr. Yuexin Liu, The Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center


The assay for transposase-accessible chromatin using sequencing employs hyperactive Tn5 transposase for highly efficient cutting of exposed DNA and simultaneous ligation of adapters which are then subject to next-generation sequencing.

Therefore, ATAC-seq has enabled the genome-wide profiling of chromatin accessibility in primary human cancers.

Unexpectedly, there is little research on cancer study by using the ATAC-seq technique with a limited number of cancer types such as prostate cancer, pancreatic cancer, and hematological malignancy.

Recently, the Cancer Genome Atlas performed ATAC-seq on 410 tumor samples derived from 404 unique donors and generated a catalog of chromatin accessibility in human cancers.

We will further integrate ATAC-seq data along with the patient clinical annotations or molecular characteristics to determine the association between chromatin accessibility in the promoter regions and patient demographics such as sex, age, tumor stage and histology, molecular subtype, and patient survival.

The Liu Research Team concluded in their OncotargetResearch Article, "chromatin accessibility has important clinical implications in human cancers and our results provide an additional perspective in tumor initiation and progression."
-end-
Sign up for free Altmetric alerts about this article

DOI - https://doi.org/10.18632/oncotarget.27584

Full text - https://www.oncotarget.com/article/27584/text/

Correspondence to - Yuexin Liu - yliu8@mdanderson.org

Keywords - ATAC-seq, chromatin accessibility, TCGA, promoter, survival

About Oncotarget

Oncotarget is a weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:

SoundCloud -https://soundcloud.com/oncotarget
Facebook -https://www.facebook.com/Oncotarget/
Twitter -https://twitter.com/oncotarget
LinkedIn -https://www.linkedin.com/company/oncotarget
Pinterest -https://www.pinterest.com/oncotarget/
Reddit -https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit http://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957x105

Impact Journals LLC

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.